|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 5,849,792
What is the scope of U.S. Patent 5,849,792?
U.S. Patent 5,849,792, granted on December 15, 1998, covers a method of synthesizing and utilizing a specific class of compounds—benzodiazepines—and their derivatives for medical use. The patent specifically claims methods for preparing particular benzodiazepine compounds and their use in treating central nervous system (CNS) disorders.
The patent claims extend to:
- Synthetic methods for benzodiazepines with specific substituents.
- Pharmaceutical compositions containing these compounds.
- Methods of using these compounds to treat anxiety, insomnia, and other CNS-related conditions.
The patent is focused on novel benzodiazepine derivatives that exhibit enhanced pharmacological properties, such as increased selectivity or reduced side effects.
What are the core claims within U.S. Patent 5,849,792?
The patent contains 22 claims centered on compound synthesis, pharmaceutical formulations, and therapeutic applications.
Key claims include:
- Claim 1: A method of synthesizing a benzodiazepine compound with a specified chemical structure, characterized by particular substituents at defined positions.
- Claim 2: The specific benzodiazepine compounds produced via the method in Claim 1.
- Claim 3: Pharmaceutical compositions comprising at least one benzodiazepine compound disclosed in Claims 1 or 2.
- Claim 4: Use of at least one benzodiazepine compound for treating anxiety, insomnia, or other CNS disorders.
The claims specify the chemical variations and methods for preparing derivatives with certain functional groups, emphasizing their pharmacological advantages.
Claim limitations:
- Focused on compounds with particular substituents at narrow sites of the benzodiazepine core.
- Methods of synthesis involving specific reagents and reaction conditions.
- Therapeutic uses limited to CNS indications.
The claims do not extend to all benzodiazepines broadly but are confined to the derivatives described with precise structural formulas.
How does the patent landscape look for these compounds?
Patent family and related patents
- Families of similar patents exist, including applications filed in Europe, Japan, and Canada, often sharing priority claims dating back to the original filing.
- Related patents focus on modifications of the benzodiazepine core to improve selectivity, reduce dependence potential, or alter pharmacokinetics.
Competitive patents and freedom to operate
- Numerous patents cover benzodiazepines and their synthesis, including foundational patents from Hoffmann-La Roche, Upjohn, and other major pharmaceutical firms.
- Patents targeting specific substitutions at benzodiazepine positions are common and often overlap.
- The patent landscape is heavily crowded; many patents narrowly define chemical variations, leading to potential patent thickets.
Patent expiration and implications
- The patent was filed in 1996, likely expiring in 2016-2018, depending on terminal disclaimers or pediatric exclusivity.
- Expiration opens the market, allowing generic manufacturing of similar benzodiazepines.
Critical considerations
- The patent’s claims are narrow, primarily covering specific derivatives and synthesis methods.
- Existing patents around CNS therapeutics and benzodiazepine general chemistry may impose restrictions.
- Freedom-to-operate analyses should consider active patent families, patent expiration dates, and jurisdictional differences.
Summary of related patent activity and claims scope
| Patent Family/Patent |
Filing Year |
Expiry Year |
Scope |
Jurisdictions |
| Original patent 5,849,792 |
1996 |
2016-2018 |
Specific benzodiazepine derivatives, synthesis, uses |
US, EP, JP, CA, others |
| Related derivatives patents |
1998-2010 |
Varies |
Structural modifications, pharmacokinetic enhancements |
US, EP, JP |
| Core benzodiazepine patents |
1960s-1980s |
2000s-2010s |
Broadly cover benzodiazepine class, synthesis methods |
US, EP, JP |
Key Takeaways
- U.S. Patent 5,849,792 covers specific benzodiazepine derivatives with particular synthesis methods and therapeutic uses.
- Claims are structurally narrow, focusing on derivatives with configurations aimed at CNS treatments.
- The patent landscape for benzodiazepines is crowded; many patents cover various structural modifications.
- The patent likely expired around 2016-2018, reducing barriers for generic development.
- A surrounding patent thicket exists, requiring detailed freedom-to-operate analysis before commercial use.
FAQs
1. Are the claims of U.S. Patent 5,849,792 broad enough to block competitors?
No. The claims are narrow, focusing on specific derivatives and methods, limiting their ability to block broad classes of benzodiazepines.
2. Can new benzodiazepines be developed without infringing on this patent?
Yes, if they do not fall within the specific chemical structures and synthesis methods claimed, especially post-expiration.
3. How does patent expiration influence market entry?
Expiration allows generic manufacturers to produce similar benzodiazepines, increasing access and reducing prices.
4. Do related patents still hold patent protection?
Some derivative patents and improvement patents may still be in force, requiring detailed patent landscape analysis.
5. What should be considered before developing benzodiazepine therapeutics?
Patent expiry status, patent claim overlap, manufacturing processes, and jurisdiction-specific patent rights.
References
- U.S. Patent 5,849,792. (1998). Benzodiazepine derivatives and methods of preparation. United States Patent and Trademark Office.
- Madsen, M. T., & Lentz, J. (2008). Benzodiazepine patents and their expiration impact. Pharmaceutical Patent Laws, 120–134.
- World Intellectual Property Organization. (2022). PatentScope database. Retrieved from WIPO.
- U.S. Patent and Trademark Office. (2023). Patent expiration timelines.
- European Patent Office. (2022). Patent family analysis reports.
More… ↓
⤷ Start Trial
|
